Nexera Pharma has obtained regulatory designation for rare disease pharmaceuticals in Korea and plans to submit an approval application for DMD treatment drug vamorolone within 2026. Long-term safety data has also been disclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4565-20260602-01.pdf","jir_short_summary":"Nexera Pharma has obtained regulatory designation for rare disease pharmaceuticals in Korea and plans to submit an approval application for DMD treatment drug vamorolone within 2026. Long-term safety data has also been disclosed.","jir_summary":"### Financial Results Overview\nNexera Pharma has obtained designation as a rare disease drug (ODD) and priority review system (GIFT) from Korea\u2019s MFDS, announcing plans to submit an approval application for DMD treatment drug vamorolone within 2026. Long-term safety data has also been published, indicating low incidences of vertebral fractures and cataracts. This is expected to facilitate early access for Korean DMD patients and enhance the company's medium- to long-term value.\n\n### Future Outlook and Corporate Activities\nThrough obtaining regulatory designations, the company aims to promote early access to innovative treatments in Korea and improve long-term business revenue and corporate value. In preparation for the 2026 approval application, the company will work closely with regulatory authorities while advancing clinical and regulatory processes. Moving forward, we will continue to develop new drugs in the rare disease field and expand globally, prioritizing meeting unmet needs of patients.","jir_financial_highlights":"Approval application plan for vamorolone in Korea: Within 2026 (New plan)\nYear of long-term dosing data announcement: March 2026 (New announcement)","jir_category":"","jir_hashtags":"#NexeraPharma, #IR, #JapaneseStocks","jir_key_figures":"Approval application plan for vamorolone in Korea: Within 2026\nLong-term safety data announcement: March 2026\nEarly access expected due to regulatory designation","jir_meta_title":"\u3010Nexera Pharma\u3011Korean Regulatory Designation and New Drug Application | June 2026","jir_meta_description":"Nexera Pharma has obtained regulatory designation for rare disease pharmaceuticals in Korea and plans to submit an approval application for DMD treatment drug vamorolone within 2026. Long-term safety data has also been disclosed.","jir_og_title":"\u3010Nexera Pharma\u3011Korean Regulatory Designation and New Drug Application | June 2026","jir_og_description":"Nexera Pharma has obtained regulatory designation for rare disease pharmaceuticals in Korea and is planning to submit an approval application for DMD treatment drug vamorolone within 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-56230","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n